Abstract
The most common term for a generic high-grade sarcoma has evolved over the years from fibrosarcoma to malignant fibrous histiocytoma (MFH), and now to high-grade undifferentiated pleomorphic sarcoma (UPS), as of the writing of the 2013 WHO sarcoma fascicle. The new nomenclature is utilized to differentiate from tumors that are truly histiocytic, i.e., histiocytic sarcoma, recognizing that their microscopic morphology is not specific for this sarcoma subtype. Specific varieties of what was called MFH in the past have proved to be unique entities. For example, myxofibrosarcoma is now a clearly defined sarcoma subtype that was formerly termed myxoid MFH. Myxofibrosarcoma occurs more frequently in the subcutaneous tissue and has infiltrating pattern (Fig. 7.1). Angiomatoid MFH is reclassified as angiomatoid fibrous histiocytoma, having mostly a benign clinical course and occurring in children and young adults. The situation is further complicated since the term MFH is still sometimes employed as a term for a high-grade bone sarcoma that lacks osteoblastic or chondroblastic differentiation (and treated most commonly as osteogenic sarcoma in children). Increasingly, the term UPS of bone is increasingly used instead of MFH of bone.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Antonescu CR, Dal Cin P, Nafa K, et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2007;46:1051–60.
Hallor KH, Mertens F, Jin Y, et al. Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma. Genes Chromosomes Cancer. 2005;44:97–102.
Romeo S, Dei Tos AP. Soft tissue tumors associated with EWSR1 translocation. Virchows Arch. 2010;456:219–34.
Tanas MR, Rubin BP, Montgomery EA, et al. Utility of FISH in the diagnosis of angiomatoid fibrous histiocytoma: a series of 18 cases. Mod Pathol. 2010;23:93–7.
Rubin BP, Nishijo K, Chen HI, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011;19:177–91.
Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–68.
Folkert MR, Singer S, Brennan MF, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J Clin Oncol. 2014;32:3236–41.
Lanning RM, Berry SL, Folkert MR, et al. Quantitative dosimetric analysis of patterns of local relapse after IMRT for primary extremity soft tissue sarcomas. CTOS Meeting Program 2013.
Mutter RW, Singer S, Zhang Z, et al. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118:518–27.
Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46:72–83.
Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755–63.
Davis EJ, Chugh R, Zhao L, et al. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Eur J Cancer. 2015;51:1794–802.
Hainsworth JD, Carrell D, Drengler RL, et al. Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer. 2004;100:2437–41.
O’Shaughnessy JA, Pluenneke R, Sternberg J, et al. Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2006;6:505–10.
Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007;109:1863–9.
Garcia-Del-Muro X, Lopez-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29:2528–33.
Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12:1045–52.
Dickson MA, D’Adamo DR, Keohan ML, et al. Phase II Trial of gemcitabine and docetaxel with bevacizumab in soft tissue sarcoma. Sarcoma. 2015;2015:532478.
Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148–53.
D’Adamo DR, Keohan M, Schuetze S, et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). J Clin Oncol. 2007;25:Abstr 10001.
George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154–60.
Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27:3126–32.
Tawbi HA-H, Burgess MA, Crowley J, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): results of SARC028—a multicenter phase II study. ASCO Meeting Abstr. 2016;34:11006.
Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096–103.
Woll PJ, Van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: interim analysis of a randomised phase III trial. J Clin Oncol. 2007;25:Abstr 10008.
Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–47.
Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003;65 Suppl 2:80–4.
Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–81.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Brennan, M.F., Antonescu, C.R., Alektiar, K.M., Maki, R.G. (2016). Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma (MFH) and Myxofibrosarcoma). In: Management of Soft Tissue Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-41906-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-41906-0_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41904-6
Online ISBN: 978-3-319-41906-0
eBook Packages: MedicineMedicine (R0)